vs
CSG SYSTEMS INTERNATIONAL INC（CSGS）とEmbecta Corp.（EMBC）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSG SYSTEMS INTERNATIONAL INCの直近四半期売上が大きい（$323.1M vs $261.2M、Embecta Corp.の約1.2倍）。Embecta Corp.の純利益率が高く（16.9% vs 2.2%、差は14.7%）。CSG SYSTEMS INTERNATIONAL INCの前年同期比売上増加率が高い（2.0% vs -0.3%）。CSG SYSTEMS INTERNATIONAL INCの直近四半期フリーキャッシュフローが多い（$55.8M vs $16.6M）。過去8四半期でCSG SYSTEMS INTERNATIONAL INCの売上複合成長率が高い（4.6% vs -4.6%）
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
Embecta Corp.は糖尿病ケアソリューションを専門とするグローバル医療テクノロジー企業です。インスリンペンニードル、注射器、輸液セット部品などを開発・製造・販売し、北米、欧州、アジア太平洋地域の患者、医療従事者、製薬企業にサービスを提供しています。
CSGS vs EMBC — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $323.1M | $261.2M |
| 純利益 | $7.0M | $44.1M |
| 粗利率 | 50.0% | 61.9% |
| 営業利益率 | 9.0% | 31.9% |
| 純利益率 | 2.2% | 16.9% |
| 売上前年比 | 2.0% | -0.3% |
| 純利益前年比 | -79.7% | — |
| EPS（希薄化後） | $0.24 | $0.74 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $323.1M | $261.2M | ||
| Q3 25 | $303.6M | $264.0M | ||
| Q2 25 | $297.1M | $295.5M | ||
| Q1 25 | $299.5M | $259.0M | ||
| Q4 24 | $316.7M | $261.9M | ||
| Q3 24 | $295.1M | $286.1M | ||
| Q2 24 | $290.3M | $272.5M | ||
| Q1 24 | $295.1M | $287.2M |
| Q4 25 | $7.0M | $44.1M | ||
| Q3 25 | $20.5M | $26.4M | ||
| Q2 25 | $12.3M | $45.5M | ||
| Q1 25 | $16.1M | $23.5M | ||
| Q4 24 | $34.5M | $0 | ||
| Q3 24 | $19.1M | $14.6M | ||
| Q2 24 | $13.8M | $14.7M | ||
| Q1 24 | $19.5M | $28.9M |
| Q4 25 | 50.0% | 61.9% | ||
| Q3 25 | 48.1% | 60.0% | ||
| Q2 25 | 49.5% | 66.7% | ||
| Q1 25 | 48.4% | 63.4% | ||
| Q4 24 | 51.3% | 60.0% | ||
| Q3 24 | 49.4% | 60.7% | ||
| Q2 24 | 47.3% | 69.8% | ||
| Q1 24 | 46.5% | 64.6% |
| Q4 25 | 9.0% | 31.9% | ||
| Q3 25 | 10.0% | 21.4% | ||
| Q2 25 | 10.0% | 31.8% | ||
| Q1 25 | 9.8% | 24.3% | ||
| Q4 24 | 13.4% | 11.0% | ||
| Q3 24 | 10.8% | 9.2% | ||
| Q2 24 | 8.8% | 20.5% | ||
| Q1 24 | 10.8% | 13.6% |
| Q4 25 | 2.2% | 16.9% | ||
| Q3 25 | 6.7% | 10.0% | ||
| Q2 25 | 4.1% | 15.4% | ||
| Q1 25 | 5.4% | 9.1% | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 6.5% | 5.1% | ||
| Q2 24 | 4.8% | 5.4% | ||
| Q1 24 | 6.6% | 10.1% |
| Q4 25 | $0.24 | $0.74 | ||
| Q3 25 | $0.73 | $0.44 | ||
| Q2 25 | $0.44 | $0.78 | ||
| Q1 25 | $0.57 | $0.40 | ||
| Q4 24 | $1.20 | $0.00 | ||
| Q3 24 | $0.67 | $0.24 | ||
| Q2 24 | $0.48 | $0.25 | ||
| Q1 24 | $0.68 | $0.50 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.0M | $201.3M |
| 総負債低いほど良い | $539.5M | — |
| 株主資本純資産 | $283.7M | $-613.1M |
| 総資産 | $1.5B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 1.90× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $180.0M | $201.3M | ||
| Q3 25 | $158.4M | $225.5M | ||
| Q2 25 | $145.9M | $230.6M | ||
| Q1 25 | $136.0M | $209.3M | ||
| Q4 24 | $161.8M | $210.0M | ||
| Q3 24 | $118.4M | $267.5M | ||
| Q2 24 | $110.4M | $275.1M | ||
| Q1 24 | $120.8M | $299.8M |
| Q4 25 | $539.5M | — | ||
| Q3 25 | $538.6M | $1.4B | ||
| Q2 25 | $537.8M | — | ||
| Q1 25 | $537.6M | — | ||
| Q4 24 | $538.5M | — | ||
| Q3 24 | $539.5M | $1.6B | ||
| Q2 24 | $540.5M | — | ||
| Q1 24 | $541.5M | — |
| Q4 25 | $283.7M | $-613.1M | ||
| Q3 25 | $289.5M | $-650.6M | ||
| Q2 25 | $290.7M | $-669.6M | ||
| Q1 25 | $283.1M | $-736.2M | ||
| Q4 24 | $282.6M | $-768.8M | ||
| Q3 24 | $288.4M | $-738.3M | ||
| Q2 24 | $273.3M | $-763.7M | ||
| Q1 24 | $269.3M | $-769.6M |
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.5B | $1.1B | ||
| Q2 25 | $1.4B | $1.2B | ||
| Q1 25 | $1.4B | $1.1B | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $1.4B | $1.3B | ||
| Q2 24 | $1.4B | $1.3B | ||
| Q1 24 | $1.3B | $1.2B |
| Q4 25 | 1.90× | — | ||
| Q3 25 | 1.86× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.90× | — | ||
| Q4 24 | 1.91× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 2.01× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $59.2M | $17.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $55.8M | $16.6M |
| FCFマージンFCF / 売上 | 17.3% | 6.4% |
| 設備投資強度設備投資 / 売上 | 1.1% | 0.2% |
| キャッシュ転換率営業CF / 純利益 | 8.46× | 0.39× |
| 直近12ヶ月FCF直近4四半期 | $141.4M | $205.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $59.2M | $17.2M | ||
| Q3 25 | $47.9M | $84.0M | ||
| Q2 25 | $37.3M | $81.2M | ||
| Q1 25 | $11.5M | $31.8M | ||
| Q4 24 | $82.5M | $-5.3M | ||
| Q3 24 | $39.5M | $26.6M | ||
| Q2 24 | $43.1M | $-2.1M | ||
| Q1 24 | $-29.4M | $24.3M |
| Q4 25 | $55.8M | $16.6M | ||
| Q3 25 | $43.9M | $76.7M | ||
| Q2 25 | $34.6M | $80.8M | ||
| Q1 25 | $7.1M | $31.7M | ||
| Q4 24 | $76.6M | $-6.8M | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $38.8M | $-11.8M | ||
| Q1 24 | $-34.1M | $20.9M |
| Q4 25 | 17.3% | 6.4% | ||
| Q3 25 | 14.5% | 29.1% | ||
| Q2 25 | 11.6% | 27.3% | ||
| Q1 25 | 2.4% | 12.2% | ||
| Q4 24 | 24.2% | -2.6% | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 13.4% | -4.3% | ||
| Q1 24 | -11.6% | 7.3% |
| Q4 25 | 1.1% | 0.2% | ||
| Q3 25 | 1.3% | 2.8% | ||
| Q2 25 | 0.9% | 0.1% | ||
| Q1 25 | 1.5% | 0.0% | ||
| Q4 24 | 1.9% | 0.6% | ||
| Q3 24 | 2.5% | 0.0% | ||
| Q2 24 | 1.5% | 3.6% | ||
| Q1 24 | 1.6% | 1.2% |
| Q4 25 | 8.46× | 0.39× | ||
| Q3 25 | 2.34× | 3.18× | ||
| Q2 25 | 3.04× | 1.78× | ||
| Q1 25 | 0.71× | 1.35× | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.07× | 1.82× | ||
| Q2 24 | 3.12× | -0.14× | ||
| Q1 24 | -1.51× | 0.84× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
